NTRK1 Fusion

CI-VAR-00001206Explore in graph →CIViC 800

Curated evidence

Evidence by cancer (6 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–6 of 6 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Infantile Fibrosarcoma2
SQSTM1::NTRK1 Fusion	Larotrectinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID6103 One patient with infantile fibrosarcoma and a NTRK1-SQSTM1 fusion was treated with larotrectinib and exhibited a partial response. Treatment was done within a multicentre, open-label, phase 1/2 study … (full text at CIViC) PMID 29606586 · Laetsch et al., 2018 · Open in CIViC	civic
SQSTM1::NTRK1 Fusion	Larotrectinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID8865 In a pediatric phase 1 trial (NCT02637687), a 2 year old with infantile fibrosarcoma of the shoulder harbored the SQSTM1-NTRK1 fusion. After two surgical resections and multiple rounds of chemotherapy… (full text at CIViC) PMID 30204247 · DuBois et al., 2018 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Lung Adenocarcinoma1
SQSTM1::NTRK1 Fusion	Larotrectinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID11574 Drilon et al (2022) assessed the efficacy and safety of larotrectinib in lung cancer patients with TRK fusions in a phase II adult/young adult trial (NCT02576431) and a phase I adult trial (NCT0212291… (full text at CIViC) PMID 35085007 · Drilon et al., 2022 · Open in CIViC	civic

Lung Non-Small Cell Carcinoma2
SQSTM1::NTRK1 Fusion	Entrectinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID1868 In 1378 cases of NSCLC screened for NTRK1 rearrangements, 2 were identified (frequency 0.1%). One patient with SQSTM1-NTRK1 was treated with entrectinib in a phase 1 study. The patient had resolution … (full text at CIViC) PMID 26565381 · Farago et al., 2015 · Open in CIViC	civic
SQSTM1::NTRK1 Fusion	Entrectinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID2950 Two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the anti… (full text at CIViC) PMID 28183697 · Drilon et al., 2017 · Open in CIViC	civic

Thyroid Gland Papillary Carcinoma1
SQSTM1::NTRK1 Fusion	Larotrectinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID11575 Bragas et al (2022) report a case study of a 50-year old female with a papillary thyroid carcinoma with multiple metastases containing a SQSTM1::NTRK1 fusion treated with larotrectinib. SQSTM1::NTRK1 … (full text at CIViC) PMID 35118995 · Bargas et al., 2022 · Open in CIViC	civic